Reviewer's report
Title:Verification of the plasma biomarker, senescence marker protein 30,
previously associated with acute liver failure using mass-spectrometry-based
proteomics
Version: 1Date:6 February 2008
Reviewer: kazuyuki Suzuki
Reviewer's report:
Major coments
ï¼#ï¼# The clinical and experimental studies by the authors show that plasma
SMP30, determined by the mass-spectrometry-based proteomics, is a potential
marker for assessing the severity of acute liver failure. However, the quantitative
measurement of plasma SMP30 by this method is cumbersome and
time-consuming. In order to fully evaluate the clinical implications of SMP30 in
acute liver failure, an ELISA assay for SMP30 needs to be developed. Some
modifications for the â##Resultsâ## and â##Discussionâ## of the manuscript
should be made.
ï¼#ï¼# Please summarize, in a new Table, the differences in liver function tests
(e.g., AST/ALT, T-Bil) in the 4 experimental groups (saline, LPS, D-GalN,
D-GalN/LPS).
ï¼#ï¼# In the D-GalN/LPS group, SMP 30 mRNA levels and protein expression
are markedly decreased in the liver, while they are increased in the plasma. This
discrepancy should to be addressed and discussed in the manuscript, including
its mechanism(s).
ï¼#ï¼# Figure 4 shows plasma SMP30 levels in 4 patients with acute liver failure
(2 with HBV infection and 2 with drug-induced liver injury). Was there a difference
in SMP30 levels between viral infection and drug-induced liver injury? It would be
useful if the authors add the information regarding the association between
plasma SMP30 and PT-INR, the degree of hepatic encephalopathy, and
prognosis.
What next?: Unable to decide on acceptance or rejection until the authors have
responded to the major compulsory revisions
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Reviewer's report
Title:Verification of the plasma biomarker, senescence marker protein 30,
previously associated with acute liver failure using mass-spectrometry-based
proteomics
Version: 1Date:6 February 2008
Reviewer: kazuyuki Suzuki
Reviewer's report:
Major coments
ï¼#ï¼# The clinical and experimental studies by the authors show that plasma
SMP30, determined by the mass-spectrometry-based proteomics, is a potential
marker for assessing the severity of acute liver failure. However, the quantitative
measurement of plasma SMP30 by this method is cumbersome and
time-consuming. In order to fully evaluate the clinical implications of SMP30 in
acute liver failure, an ELISA assay for SMP30 needs to be developed. Some
modifications for the â##Resultsâ## and â##Discussionâ## of the manuscript
should be made.
ï¼#ï¼# Please summarize, in a new Table, the differences in liver function tests
(e.g., AST/ALT, T-Bil) in the 4 experimental groups (saline, LPS, D-GalN,
D-GalN/LPS).
ï¼#ï¼# In the D-GalN/LPS group, SMP 30 mRNA levels and protein expression
are markedly decreased in the liver, while they are increased in the plasma. This
discrepancy should to be addressed and discussed in the manuscript, including
its mechanism(s).
ï¼#ï¼# Figure 4 shows plasma SMP30 levels in 4 patients with acute liver failure
(2 with HBV infection and 2 with drug-induced liver injury). Was there a difference
in SMP30 levels between viral infection and drug-induced liver injury? It would be
useful if the authors add the information regarding the association between
plasma SMP30 and PT-INR, the degree of hepatic encephalopathy, and
prognosis.
What next?: Unable to decide on acceptance or rejection until the authors have
responded to the major compulsory revisions
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Please review this paper.
user
Reviewer's report
Title:Verification of the plasma biomarker, senescence marker protein 30,
previously associated with acute liver failure using mass-spectrometry-based
proteomics
Version: 1Date:6 February 2008
Reviewer: kazuyuki Suzuki
Reviewer's report:
Major coments
ï¼#ï¼# The clinical and experimental studies by the authors show that plasma
SMP30, determined by the mass-spectrometry-based proteomics, is a potential
marker for assessing the severity of acute liver failure. However, the quantitative
measurement of plasma SMP30 by this method is cumbersome and
time-consuming. In order to fully evaluate the clinical implications of SMP30 in
acute liver failure, an ELISA assay for SMP30 needs to be developed. Some
modifications for the â##Resultsâ## and â##Discussionâ## of the manuscript
should be made.
ï¼#ï¼# Please summarize, in a new Table, the differences in liver function tests
(e.g., AST/ALT, T-Bil) in the 4 experimental groups (saline, LPS, D-GalN,
D-GalN/LPS).
ï¼#ï¼# In the D-GalN/LPS group, SMP 30 mRNA levels and protein expression
are markedly decreased in the liver, while they are increased in the plasma. This
discrepancy should to be addressed and discussed in the manuscript, including
its mechanism(s).
ï¼#ï¼# Figure 4 shows plasma SMP30 levels in 4 patients with acute liver failure
(2 with HBV infection and 2 with drug-induced liver injury). Was there a difference
in SMP30 levels between viral infection and drug-induced liver injury? It would be
useful if the authors add the information regarding the association between
plasma SMP30 and PT-INR, the degree of hepatic encephalopathy, and
prognosis.
What next?: Unable to decide on acceptance or rejection until the authors have
responded to the major compulsory revisions
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
assistant